@article{3e1e9f2c40e548d4af37cd1b7a4acb87,
title = "EEG as a translational biomarker and outcome measure in fragile X syndrome",
author = "Aisling Kenny and Damien Wright and Stanfield, {Andrew C.}",
note = "Funding Information: This review was part of a project funded by the Simons Foundation for Autism Research (The Simons Institute for the Developing Brain), the Patrick Wild Centre (University of Edinburgh) and a Wellcome Trust (Institutional Strategic Support Fund) awarded to Andrew Stanfield. The authors thank Professor Peter Kind for proofreading the manuscript. Funding Information: Andrew Stanfield has received grant funding from Novartis and Roche, including for trials of mGluR5 antagonists in fragile X syndrome. Aisling Kenny and Damien Wright declare no conflict of interest. Publisher Copyright: {\textcopyright} 2022, The Author(s).",
year = "2022",
month = jan,
day = "24",
doi = "10.1038/s41398-022-01796-2",
language = "English",
volume = "12",
journal = "Translational Psychiatry",
issn = "2158-3188",
publisher = "Nature Publishing Group",
number = "1",
}